查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1489375

2030 年临床试验影像市场预测：按产品、影像方式、应用、最终用户和地区进行的全球分析

Clinical Trial Imaging Market Forecasts to 2030 - Global Analysis By Product (Software and Services), Imaging Modality, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球临床试验影像市场规模为 23.5 亿美元，预计在预测期内复合年增长率为 8.6%，到 ​​2030 年将达到 45.2 亿美元。

临床试验影像包括各种影像技术，用于评估临床试验中药物、医疗设备和介入措施的安全性和有效性。这些影像对于评估疾病进展、治疗效果和潜在副作用至关重要。透过提供详细的解剖和功能讯息，诊断影像在确定临床试验的成功、帮助决策流程和推进医学研究方面发挥关键作用。

根据ClinicalTrialsarena.com统计，2017年至2022年间，亚太地区（APAC）临床试验将出现约10%的显着成长率，超过美国、欧洲和RoW等其他主要地区的成长率。

全球临床试验数量不断增加

对药物开发和个人化医疗的日益关注增加了对准确可靠的影像技术来评估治疗的有效性和安全性的需求。临床试验利用 MRI、CT、PET 和超音波等影像方式进行病患分层、治疗监测和终点评估。随着製药和生物技术公司寻求先进的诊断影像解决方案来支持其研究活动，临床试验中诊断影像需求的激增正在推动市场成长。

解释上的变化

临床试验影像中的解释变异性是由于设备、通讯协定和读者专业知识的差异导致影像解释不一致造成的。儘管努力标准化通讯协定并培训读者，但变异性仍然存在并影响资料可靠性和测试结果。这会降低人们对影像资料品质的信心、增加试验持续时间以及增加与重复读数和结果争议相关的成本，从而阻碍市场成长。

转向个人化医疗

临床试验影像在患者分层、治疗监测和治疗效果评估中发挥重要作用，满足个人化医疗的目标。透过识别特定的生物标誌物，影像技术有助于选择合适的患者进行临床试验、优化治疗方法和评估治疗效果。个人化医疗对诊断影像的日益依赖正在推动临床试验影像市场的成长。

实施成本高

临床试验影像的高实施成本是由于昂贵的设备、基础设施需求和熟练的人员要求所造成的。这些成本构成了巨大的障碍，特别是对于中小企业 (SME) 和学术机构而言，限制了他们将影像纳入临床试验的能力。这一限制限制了成像技术的采用并限制了以成像为终点进行的临床试验的范围，从而阻碍了市场成长。

COVID-19 的影响

COVID-19 大流行对临床试验影像市场产生了重大影响。虽然疫情最初由于关闭和旅行限製而扰乱了临床试验活动，但它也凸显了远端监控和分散测试的重要性。虚拟和混合测试模型的快速采用增加了对支援远端资料收集和分析的成像解决方案的需求。此外，对感染疾病研究和疫苗开发的关注进一步刺激了新冠临床试验对影像技术的需求，重塑了市场格局。

预计 X 光部分在预测期内将是最大的

X射线产业预计将出现良好的成长。 X 光显像模式由于其多功能性和广泛可用性而对于临床试验成像至关重要。 X 光可非侵入性地显示解剖结构，并可侦测骨骼异常、肿瘤和其他病灶。快速成像、相对较低的成本和完善的方案使其适合大规模临床试验。此外，数位放射成像和双能量 X 射线吸收测定法等进步增强了其功能，并促进了其在不同治疗领域的采用。

预计神经系统测试产业在预测期内将经历最高的复合年增长率。

神经病学临床试验领域预计在预测期内将出现最高的复合年增长率。神经病学临床试验中的临床试验影像提供了一种评估大脑结构和功能变化的非侵入性方法，这对于开发阿兹海默症、帕金森氏症和多发性硬化症等神经系统疾病的治疗方法至关重要。随着神经系统疾病盛行率的增加和需要更有效的治疗方法，神经系统临床临床实验的应用在简化临床实验、早期发现疾病和促进新治疗方法。

占比最大的地区：

预计亚太地区在预测期内将占据最大的市场占有率。医疗保健基础设施投资的增加、临床试验活动的增加以及患者数量的增加正在促进该地区的市场扩张。亚太地区的成本优势正在吸引製药和生物技术公司在该地区进行临床试验。此外，支持性法律规范和影像技术的进步进一步刺激了市场成长。由于对精准医疗的重视以及对创新治疗方法的需求不断增长，亚太地区临床试验影像市场有望实现显着成长和机会。

复合年增长率最高的地区：

由于其成熟度、技术先进性和坚实的基础设施，预计北美在预测期内将呈现最高的复合年增长率。该地区拥有完善的医疗保健体系和 FDA 等强大的法规结构，吸引了大量的全球临床试验。大型製药企业的存在以及强大的研发活动也支持了市场成长。北美还拥有技术熟练的劳动力、尖端成像技术和大量患者群体的优势。这些因素共同促成了该地区的市场主导地位。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球临床试验影像市场：按产品

  • 软体
    • 影像分析软体
    • 电子资料撷取(EDC) 软体
    • 影像资料管理软体
    • 3D影像软体
  • 服务
    • 影像核心实验室服务
    • 现场影像服务
    • 影像诊断咨询服务
    • 监理合规服务

第六章 世界各地的临床试验影像地点：依影像方式分类

  • 磁振造影(MRI)
  • 电脑断层扫描 (CT)
  • 正子断层扫描 (PET)
  • 单光子发射电脑断层扫描 (SPECT)
  • 超音波
  • X射线
  • 其他成像方式

第七章全球临床试验影像市场：依应用分类

  • 肿瘤学测试
  • 神经学检查
  • 心臟病学检查
  • 风湿病检查
  • 内分泌检查
  • 其他用途

第八章全球临床试验影像市场：依最终使用者分类

  • 合约研究组织（CRO）
  • 生技公司
  • 学术研究所
  • 其他最终用户

第九章全球临床试验影像市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第10章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司概况

  • Biomedical Systems
  • Cardinal Health
  • ICON plc
  • IXICO plc
  • BioTelemetry Inc.
  • Covance Inc.
  • Parexel International Corporation
  • Clario Medical Imaging Inc.
  • Intrinsic Imaging LLC
  • Radiant Sage LLC
  • ERT（eResearchTechnology）
  • Navitas Life Sciences
  • Resonance Health
  • ProScan Imaging
  • Medpace
Product Code: SMRC26161

According to Stratistics MRC, the Global Clinical Trial Imaging Market is accounted for $2.35 billion in 2023 and is expected to reach $4.52 billion by 2030 growing at a CAGR of 8.6% during the forecast period. Clinical Trial Imaging involves the use of various imaging techniques to assess the safety and efficacy of drugs, medical devices, or interventions in clinical trials. These images are crucial for evaluating disease progression, treatment response, and potential side effects. By providing detailed anatomical and functional information, imaging plays a vital role in determining the success of clinical trials, aiding in decision-making processes, and advancing medical research.

According to Clinicaltrialsarena.com, in the period between 2017 and 2022, the Asia-Pacific (APAC) region experienced a remarkable growth rate of around 10% in clinical trials, surpassing the growth rate of other major regions such as the US, Europe, and RoW.

Market Dynamics:

Driver:

Mounting number of clinical trials globally

With an increasing focus on drug development and personalized medicine, there's a growing demand for accurate and reliable imaging technologies to assess treatment efficacy and safety. Clinical trials utilize imaging modalities such as MRI, CT, PET, and ultrasound for patient stratification, treatment monitoring, and endpoint assessment. This surge in demand for imaging in clinical trials boosts market growth as pharmaceutical and biotechnology companies seek advanced imaging solutions to support their research endeavours.

Restraint:

Interpretation variabilities

Interpretation variabilities in clinical trial imaging stem from differences in equipment, protocols, and reader expertise, leading to inconsistent image interpretations. Despite efforts to standardize protocols and train readers, variability persists, impacting data reliability and study outcomes. This hampers market growth by eroding confidence in imaging data quality, prolonging study timelines, and increasing costs associated with repeated readings or disputes over results.

Opportunity:

Shift towards personalized medicine

Clinical trial imaging plays a crucial role in patient stratification, treatment monitoring, and assessing treatment response, aligning with the objectives of personalized medicine. By enabling the identification of specific biomarkers, imaging technologies facilitate the selection of suitable patients for clinical trials, optimization of treatment regimens, and evaluation of therapeutic efficacy. This increased reliance on imaging in personalized medicine fuels the growth of the Clinical Trial Imaging market.

Threat:

High implementation costs

High implementation costs in clinical trial imaging stem from expensive equipment, infrastructure needs, and skilled personnel requirements. These costs pose a significant barrier, particularly for small and medium-sized enterprises (SMEs) and academic institutions, limiting their ability to incorporate imaging into clinical trials. This limitation hampers market growth by constraining the adoption of imaging techniques and restricting the scope of clinical trials conducted with imaging endpoints.

Covid-19 Impact

The covid-19 pandemic has significantly impacted the clinical trial imaging market. While the pandemic initially led to disruptions in clinical trial activities due to lockdowns and travel restrictions, it also highlighted the importance of remote monitoring and decentralized trials, where imaging plays a critical role. The adoption of virtual and hybrid trial models surged, driving demand for imaging solutions that support remote data collection and analysis. Additionally, the focus on infectious disease research and vaccine development further stimulated demand for imaging technologies in covid clinical trials, reshaping the market landscape.

The X-ray segment is expected to be the largest during the forecast period

The X-ray segment is estimated to have a lucrative growth. X-ray imaging modality is integral to Clinical Trial Imaging due to its versatility and widespread availability. It offers non-invasive visualization of anatomical structures and can detect skeletal abnormalities, tumours, and other pathologies. Its rapid acquisition, relatively low cost, and established protocols make it suitable for large-scale trials. Additionally, advancements like digital radiography and dual-energy X-ray absorptiometry enhance its capabilities, driving its adoption in diverse therapeutic areas.

The neurology trials segment is expected to have the highest CAGR during the forecast period

The neurology trials segment is anticipated to witness the highest CAGR growth during the forecast period. Clinical Trial Imaging in Neurology Trials offers non-invasive methods to assess structural and functional changes in the brain, crucial for developing treatments for neurological disorders like Alzheimer's, Parkinson's, and multiple sclerosis. With the rising prevalence of neurological disorders and the demand for more effective therapies, it plays a vital role in enhancing trial efficiency, enabling early disease detection, and advancing the development of novel treatments, driving its application in neurology trials.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period. The region's increasing investment in healthcare infrastructure, rising clinical trial activity, and a large patient pool contribute to market expansion. APAC offers cost advantages, attracting pharmaceutical and biotechnology companies to conduct clinical trials in the region. Additionally, supportive regulatory frameworks and advancements in imaging technologies further stimulate market growth. With a growing emphasis on precision medicine and the need for innovative therapies, the APAC Clinical Trial Imaging market is poised for significant development and opportunities.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to its maturity, technological advancements, and robust infrastructure. With a well-established healthcare system and strong regulatory frameworks like the FDA, the region attracts a significant share of global clinical trials. The presence of leading pharmaceutical and biotechnology companies, coupled with a high level of research and development activities, drives market growth. Additionally, North America benefits from a skilled workforce, access to cutting-edge imaging technologies, and a large patient population. These factors collectively contribute to the region's dominance in the market.

Key players in the market

Some of the key players profiled in the Clinical Trial Imaging Market include Biomedical Systems, Cardinal Health, ICON plc, IXICO plc, BioTelemetry Inc., Covance Inc., Parexel International Corporation, Clario Medical Imaging Inc., Intrinsic Imaging LLC, Radiant Sage LLC, ERT (eResearchTechnology), Navitas Life Sciences, Resonance Health, ProScan Imaging, Medpace.

Key Developments:

In May 2023, Cleerly has partnered with ProScan Imaging to provide personalized solutions for cardiac health, which involve analyzing and devising treatment strategies for cardiovascular issues.

In March 2023, ICON PLC (Ireland) announced a strategic partnership with LEO Pharma (Denmark) to scale clinical trial execution that is patient-centric and cost effective, and which will support the company's overall ambition of building one of the most effective and efficient clinical portfolio execution organisations in the industry.

In March 2023, Clario (US), announced the launch of a cutting-edge cloud-based image viewer tool for sponsors and contract research organizations to view images related to their clinical trials.

Products Covered:

  • Software
  • Services

Imaging Modalities Covered:

  • Magnetic Resonance Imaging (MRI)
  • Computed Tomography (CT)
  • Positron Emission Tomography (PET)
  • Single-Photon Emission Computed Tomography (SPECT)
  • Ultrasound
  • X-Ray
  • Other Imaging Modalities

Applications Covered:

  • Oncology Trials
  • Neurology Trials
  • Cardiology Trials
  • Rheumatology Trials
  • Endocrinology Trials
  • Other Applications

End Users Covered:

  • Contract Research Organizations (CROs)
  • Biotechnology Companies
  • Academic and Research Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Clinical Trial Imaging Market, By Product

  • 5.1 Introduction
  • 5.2 Software
    • 5.2.1 Image Analysis Software
    • 5.2.2 Electronic Data Capture (EDC) Software
    • 5.2.3 Imaging Data Management Software
    • 5.2.4 3D Imaging Software
  • 5.3 Services
    • 5.3.1 Imaging Core Lab Services
    • 5.3.2 Site Imaging Services
    • 5.3.3 Imaging Consultation Services
    • 5.3.4 Regulatory Compliance Services

6 Global Clinical Trial Imaging Market, By Imaging Modality

  • 6.1 Introduction
  • 6.2 Magnetic Resonance Imaging (MRI)
  • 6.3 Computed Tomography (CT)
  • 6.4 Positron Emission Tomography (PET)
  • 6.5 Single-Photon Emission Computed Tomography (SPECT)
  • 6.6 Ultrasound
  • 6.7 X-Ray
  • 6.8 Other Imaging Modalities

7 Global Clinical Trial Imaging Market, By Application

  • 7.1 Introduction
  • 7.2 Oncology Trials
  • 7.3 Neurology Trials
  • 7.4 Cardiology Trials
  • 7.5 Rheumatology Trials
  • 7.6 Endocrinology Trials
  • 7.7 Other Applications

8 Global Clinical Trial Imaging Market, By End User

  • 8.1 Introduction
  • 8.2 Contract Research Organizations (CROs)
  • 8.3 Biotechnology Companies
  • 8.4 Academic and Research Institutes
  • 8.5 Other End Users

9 Global Clinical Trial Imaging Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Biomedical Systems
  • 11.2 Cardinal Health
  • 11.3 ICON plc
  • 11.4 IXICO plc
  • 11.5 BioTelemetry Inc.
  • 11.6 Covance Inc.
  • 11.7 Parexel International Corporation
  • 11.8 Clario Medical Imaging Inc.
  • 11.9 Intrinsic Imaging LLC
  • 11.10 Radiant Sage LLC
  • 11.11 ERT (eResearchTechnology)
  • 11.12 Navitas Life Sciences
  • 11.13 Resonance Health
  • 11.14 ProScan Imaging
  • 11.15 Medpace

List of Tables

  • Table 1 Global Clinical Trial Imaging Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Clinical Trial Imaging Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Clinical Trial Imaging Market Outlook, By Software (2021-2030) ($MN)
  • Table 4 Global Clinical Trial Imaging Market Outlook, By Image Analysis Software (2021-2030) ($MN)
  • Table 5 Global Clinical Trial Imaging Market Outlook, By Electronic Data Capture (EDC) Software (2021-2030) ($MN)
  • Table 6 Global Clinical Trial Imaging Market Outlook, By Imaging Data Management Software (2021-2030) ($MN)
  • Table 7 Global Clinical Trial Imaging Market Outlook, By 3D Imaging Software (2021-2030) ($MN)
  • Table 8 Global Clinical Trial Imaging Market Outlook, By Services (2021-2030) ($MN)
  • Table 9 Global Clinical Trial Imaging Market Outlook, By Imaging Core Lab Services (2021-2030) ($MN)
  • Table 10 Global Clinical Trial Imaging Market Outlook, By Site Imaging Services (2021-2030) ($MN)
  • Table 11 Global Clinical Trial Imaging Market Outlook, By Imaging Consultation Services (2021-2030) ($MN)
  • Table 12 Global Clinical Trial Imaging Market Outlook, By Regulatory Compliance Services (2021-2030) ($MN)
  • Table 13 Global Clinical Trial Imaging Market Outlook, By Imaging Modality (2021-2030) ($MN)
  • Table 14 Global Clinical Trial Imaging Market Outlook, By Magnetic Resonance Imaging (MRI) (2021-2030) ($MN)
  • Table 15 Global Clinical Trial Imaging Market Outlook, By Computed Tomography (CT) (2021-2030) ($MN)
  • Table 16 Global Clinical Trial Imaging Market Outlook, By Positron Emission Tomography (PET) (2021-2030) ($MN)
  • Table 17 Global Clinical Trial Imaging Market Outlook, By Single-Photon Emission Computed Tomography (SPECT) (2021-2030) ($MN)
  • Table 18 Global Clinical Trial Imaging Market Outlook, By Ultrasound (2021-2030) ($MN)
  • Table 19 Global Clinical Trial Imaging Market Outlook, By X-Ray (2021-2030) ($MN)
  • Table 20 Global Clinical Trial Imaging Market Outlook, By Other Imaging Modalities (2021-2030) ($MN)
  • Table 21 Global Clinical Trial Imaging Market Outlook, By Application (2021-2030) ($MN)
  • Table 22 Global Clinical Trial Imaging Market Outlook, By Oncology Trials (2021-2030) ($MN)
  • Table 23 Global Clinical Trial Imaging Market Outlook, By Neurology Trials (2021-2030) ($MN)
  • Table 24 Global Clinical Trial Imaging Market Outlook, By Cardiology Trials (2021-2030) ($MN)
  • Table 25 Global Clinical Trial Imaging Market Outlook, By Rheumatology Trials (2021-2030) ($MN)
  • Table 26 Global Clinical Trial Imaging Market Outlook, By Endocrinology Trials (2021-2030) ($MN)
  • Table 27 Global Clinical Trial Imaging Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 28 Global Clinical Trial Imaging Market Outlook, By End User (2021-2030) ($MN)
  • Table 29 Global Clinical Trial Imaging Market Outlook, By Contract Research Organizations (CROs) (2021-2030) ($MN)
  • Table 30 Global Clinical Trial Imaging Market Outlook, By Biotechnology Companies (2021-2030) ($MN)
  • Table 31 Global Clinical Trial Imaging Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
  • Table 32 Global Clinical Trial Imaging Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.